UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 38

Sortiert nach

Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06–2018 study)

Lung cancer (Amsterdam, Netherlands), 2024-07, Vol.193, p.107843, Article 107843

2024

Volltextzugriff (PDF)

Lung cancer survivors and employment: A systematic review

Lung cancer (Amsterdam, Netherlands), 2019-05, Vol.131, p.31-39

2019

Volltextzugriff (PDF)

Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network

European journal of cancer (1990), 2022-02, Vol.162, p.118-127

2022

Volltextzugriff (PDF)

Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in France

Oncology, 2018-01, Vol.95 (6), p.337-343

2018

Volltextzugriff (PDF)

Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)

Targeted oncology, 2023-11, Vol.18 (6), p.905-914

2023

Volltextzugriff (PDF)

Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non–Small-cell Lung Cancer: A Phase I Study

Clinical lung cancer, 2018-05, Vol.19 (3), p.e277-e285

2018

Volltextzugriff (PDF)

Alveolar hemorrhage in anti-basement membrane antibody disease: a series of 28 cases

Medicine (Baltimore), 2007-05, Vol.86 (3), p.181-193

2007

Volltextzugriff (PDF)

Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial

Cancers, 2019-11, Vol.11 (12), p.1835

2019

Volltextzugriff (PDF)

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers

The European respiratory journal, 2015-05, Vol.45 (5), p.1403-1414

2015

Volltextzugriff (PDF)

Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC

Journal of thoracic oncology, 2021-05, Vol.16 (5), p.807-816

2021

Volltextzugriff (PDF)

A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial)

European journal of cancer (1990), 2013-08, Vol.49 (12), p.2654-2664

2013

Volltextzugriff (PDF)

Association between lung cancer somatic mutations and occupational exposure in never-smokers

The European respiratory journal, 2017-10, Vol.50 (4), p.1700716-1700716

2017

Volltextzugriff (PDF)

No impact of passive smoke on the somatic profile of lung cancers in never-smokers

The European respiratory journal, 2015-05, Vol.45 (5), p.1415-1425

2015

Volltextzugriff (PDF)

PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients

Clinical lung cancer, 2022-05, Vol.23 (3), p.e243-e246

2022

Volltextzugriff (PDF)

Explore ALK: Alectinib activity in patients with ALK+ metastatic non-small cell lung cancer—A national real world analysis (GFPC 03-2019)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9092-9092

2023

Volltextzugriff (PDF)

Second-line therapy in elderly patients with advanced nonsmall cell lung cancer

The European respiratory journal, 2014, Vol.43 (1), p.240-249

2014

Volltextzugriff (PDF)

First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)

Cancer Immunology, Immunotherapy, 2023-01, Vol.72 (1), p.91-99

2023

Volltextzugriff (PDF)

Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer

Journal of cancer research and clinical oncology, 2023-11, Vol.149 (16), p.15095-15102

2023

Volltextzugriff (PDF)

Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients

La Presse médicale (1983), 2019-04, Vol.48 (4), p.e199-e207

2019

Volltextzugriff (PDF)

First-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥ 50%) advanced non-small cell lung cancer (aNSCLC) in the real world: A national French bispective multicentric cohort—ESCKEYP trial (GFPC 05-2018)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9091-9091

2021

Volltextzugriff (PDF)

Outcomes of thymic epithelial tumors (TETs) with pleural metastases: Real-world insight from RYTHMIC

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.8578-8578

2021

Volltextzugriff (PDF)

Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit

Supportive care in cancer, 2019-05, Vol.27 (5), p.1679-1686

2019

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(38)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Humans
(23)
Life Sciences
(18)
Oncology
(18)
Female
(17)
Male
(17)
Middle Aged
(14)
Aged
(13)
Respiratory System
(12)
Lung Cancer
(10)
Cancer
(9)
Lung Neoplasms - Drug Therapy
(9)
Prospective Studies
(9)
Lung Neoplasms - Pathology
(8)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(7)
Adult
(6)
Aged, 80 And Over
(6)
Carcinoma, Non-Small-Cell Lung - Pathology
(6)
Cohort Studies
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06–2018 study)

Lung cancer survivors and employment: A systematic review

Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network

Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in France

Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)

Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non–Small-cell Lung Cancer: A Phase I Study

Alveolar hemorrhage in anti-basement membrane antibody disease: a series of 28 cases

Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers

Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC

A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial)

Association between lung cancer somatic mutations and occupational exposure in never-smokers

No impact of passive smoke on the somatic profile of lung cancers in never-smokers

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients

Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018

Explore ALK: Alectinib activity in patients with ALK+ metastatic non-small cell lung cancer—A national real world analysis (GFPC 03-2019)

Second-line therapy in elderly patients with advanced nonsmall cell lung cancer

First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)

Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer

Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer

Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients

First-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥ 50%) advanced non-small cell lung cancer (aNSCLC) in the real world: A national French bispective multicentric cohort—ESCKEYP trial (GFPC 05-2018)

Outcomes of thymic epithelial tumors (TETs) with pleural metastases: Real-world insight from RYTHMIC

Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit

Suchergebnisse filtern